Bipolar I Disorder Exacerbation Following COVID-19 Vaccination
A 60-year-old African American female with previously stable bipolar I disorder (BD1) presented after three weeks of depressed mood, anxiety, and decreased need for sleep. Patient Health Questionnaire-9 (PHQ-9) - a widely used tool for diagnosing depression was administered and her score was 5. Her symptoms began within a week of receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine. She was assessed a PHQ-9 score of 0 17 days before vaccination. Her prescription of risperidone 2mg was temporarily increased to 3mg, and her symptoms returned to baseline after two weeks.
A 40-year-old white male with previously stable BD1 and attention deficit hyperactivity disorder (ADHD) was voluntarily hospitalized due to a mixed episode with psychotic features. His symptoms began after receiving the second dose of the Moderna COVID-19 vaccine and subsequently worsened after he discontinued his medications five days prior to admission. His symptoms stabilized after 10 days of treatment.
Guina J, Barlow S, Gutierrez D. Bipolar I Disorder Exacerbation Following COVID-19 Vaccination. Innov Clin Neurosci. 2022 Jul-Sep;19(7-9):9-11. PMID: 36204171; PMCID: PMC9507143.